{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:32:53Z","timestamp":1790181173064,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Immunotherapies targeting the PD-1\/PD-L1 checkpoint axis are of growing interest for the treatment of mesenchymal neoplasms. However, PD-L1 expression and tumor-associated lymphocytes have not been well-investigated in uterine smooth muscle tumors. Forty-nine uterine smooth muscle tumors (23 leiomyosarcomas, 8 smooth muscle tumors of uncertain malignant potential [STUMP], 7 atypical leiomyomas, and 11 benign leiomyomas) were evaluated for tumoral and tumor-associated immune PD-L1 expression and tumor-associated T-cell infiltration. ALK immunohistochemistry was performed to exclude inflammatory myofibroblastic tumors. Tumor PD-L1 expression was seen in 70% of leiomyosarcomas and 14% of atypical leiomyomas; no cases of STUMP or benign leiomyoma demonstrated tumoral PD-L1. PD-L1 positivity was seen in tumor-associated immune cells in 78% of leiomyosarcomas, 25% of STUMP, no cases of atypical leiomyomas, and 9% of benign leiomyomas. Of the 23 leiomyosarcomas, 15 (65%) had a combined positive score \u22651, while of the 26 other uterine smooth muscle tumors, only 2 (8%) had a combined positive score \u22651. Tumor-associated CD8+ cells were highest among leiomyosarcomas (mean: 87\/high-power fields vs. 17\/high-power fields for nonleiomyosarcomas), and were significantly associated with PD-L1 expression. One PD-L1<jats:sup>+<\/jats:sup>, CD8-enriched leiomyosarcoma showed an ALK overexpression suggesting possible classification as inflammatory myofibroblastic tumor, but otherwise lacked morphologic features of this entity. Leiomyosarcomas demonstrate significantly higher PD-L1 expression and cytotoxic T-cell infiltration when compared with other uterine smooth muscle tumors. These data suggest the possibility that treatment with targeted immunotherapy may be appropriate in a selected population of patients with leiomyosarcoma and, potentially, in related tumors bearing <jats:italic toggle=\"yes\">ALK<\/jats:italic> rearrangements.<\/jats:p>","DOI":"10.1097\/pas.0000000000001254","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T03:20:31Z","timestamp":1555903231000},"page":"792-801","source":"Crossref","is-referenced-by-count":31,"title":["PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors"],"prefix":"10.1097","volume":"43","author":[{"given":"Elisheva D.","family":"Shanes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00000478-199406000-00001","article-title":"Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases","volume":"18","author":"Bell","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"suppl","key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/IGC.0000000000000372","article-title":"Trends in the treatment of uterine leiomyosarcoma in the medicare population","volume":"25","author":"Foley","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"key":"R7-20230922","first-page":"172","article-title":"Pure mesenchymal neoplasms of the uterine corpus: selected problems","volume":"5","author":"Kempson","year":"1988","journal-title":"Semin Diagn Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2009.02.020","article-title":"Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis","volume":"113","author":"Guntupalli","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00006250-199406000-00023","article-title":"Uterine smooth-muscle tumors of uncertain malignant potential","volume":"83","author":"Peters","year":"1994","journal-title":"Obstet Gynecol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/PAS.0b013e3181a02d1c","article-title":"Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases","volume":"33","author":"Ip","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0b013e3182893f36","article-title":"Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases","volume":"37","author":"Ly","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1634\/theoncologist.2018-0095","article-title":"Systemic treatment of metastatic\/recurrent uterine leiomyosarcoma: a changing paradigm","volume":"23","author":"Arend","year":"2018","journal-title":"Oncologist"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.coc.0000156919.04133.98","article-title":"On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus","volume":"28","author":"Dusenbery","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-018-0526-0","article-title":"Options for adjuvant therapy for uterine leiomyosarcoma","volume":"19","author":"Friedman","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"R16-20230922","first-page":"JCO1800454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG oncology\/gynecologic oncology group study","author":"Hensley","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2013.08.037","article-title":"Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?","volume":"131","author":"Ricci","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl; abstr 5581","key":"R24-20230922","article-title":"Pembrolizumab in advanced endometrial cancer: preliminary results from the phase ib KEYNOTE-028 study","volume":"34","author":"Ott","year":"2016","journal-title":"J Clin Oncol"},{"key":"R25-20230922","first-page":"5955","article-title":"Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research","volume":"37","author":"Gadducci","year":"2017","journal-title":"Anticancer Res"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1758834017708742","article-title":"Pembrolizumab in cervical cancer: latest evidence and clinical usefulness","volume":"9","author":"Borcoman","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","article-title":"Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials","volume":"5","author":"Groisberg","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00428-018-2428-8","article-title":"Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors","volume":"473","author":"Pt\u00e1kov\u00e1","year":"2018","journal-title":"Virchows Arch"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/PAS.0000000000001083","article-title":"ALK-rearranged tumors are highly enriched in the STUMP subcategory of uterine tumors","volume":"43","author":"Devereaux","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5858\/arpa.2011-0341-OA","article-title":"ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract","volume":"136","author":"Fuehrer","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2217\/fon-2017-0565","article-title":"The current landscape of early drug development for patients with sarcoma in the immunotherapy era","volume":"14","author":"Sebio","year":"2018","journal-title":"Future Oncol"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-018-1658-5","article-title":"Status of programmed death-ligand 1 expression in sarcomas","volume":"16","author":"Park","year":"2018","journal-title":"J Transl Med"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/1541-7786.MCR-18-1075","article-title":"Discovery and characterization of recurrent, targetable ALK fusions in leiomyosarcoma","volume":"17","author":"Davis","year":"2019","journal-title":"Mol Cancer Res"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"27595","DOI":"10.18632\/oncotarget.25137","article-title":"Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with ALK rearrangement and loss of 14q","volume":"9","author":"Holzmann","year":"2018","journal-title":"Oncotarget"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-018-0359-1","article-title":"Immunohistochemical expression and prognostic value of PD-L1 in extrapulmonary small cell carcinoma: a single institution experience","volume":"6","author":"Salhab","year":"2018","journal-title":"J Immunother Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201906000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:47:33Z","timestamp":1695422853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201906000-00008"}},"subtitle":["Implications for Immunotherapy"],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001254","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}